High-risk Neuroblastoma
Showing 1 - 25 of >10,000
Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)
Recruiting
- Neuroblastoma
- Ganglioneuroblastoma
- monoclonal antibodies GD2
-
Moscow, Russian FederationResearch Institute of Pediatric Hematology, Oncology and Immunol
Oct 4, 2023
High-risk Neuroblastoma Trial in China (Dinutuximab Beta, 13 cis retinoic acid)
Active, not recruiting
- High-risk Neuroblastoma
- Dinutuximab Beta
- 13 cis retinoic acid
-
Beijing, Beijing, China
- +3 more
Dec 7, 2022
Neuroblastoma Trial in Minneapolis (Thiotepa, Cyclophosphamide, Melphalan)
Recruiting
- Neuroblastoma
- Thiotepa
- +6 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 2, 2022
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma Trial in United States (OPT-821 (QS-21), oral ß-glucan)
Recruiting
- Neuroblastoma
- +2 more
- OPT-821 (QS-21)
- oral β-glucan
-
Basking Ridge, New Jersey
- +6 more
Sep 21, 2023
Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)
Terminated
- Neuroblastoma
- antibody ch14.18
- +4 more
-
Cologne, GermanyUniversity of Cologne
Nov 3, 2022
Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)
Terminated
- Neuroblastoma Recurrent
- Naxitamab and GM-CSF in combination with irinotecan and temozolomide
-
Hong Kong, Hong Kong
- +2 more
Nov 8, 2022
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)
Not yet recruiting
- Refractory Neuroblastoma
- +2 more
- GPC2 CAR T cells
- (no location specified)
Dec 21, 2022
Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)
Active, not recruiting
- Neuroblastoma
- Hu3F8
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 1, 2022
Neuroblastoma, Pediatric Cancer Trial in New York (Cyclophosphamide, Topotecan, Vincristine)
Recruiting
- Neuroblastoma
- Pediatric Cancer
- Cyclophosphamide
- +7 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 11, 2023
Neuroblastoma Trial in New York (dietary supplement, drug, biological)
Recruiting
- Neuroblastoma
- β-glucan
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 5, 2022
Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)
Active, not recruiting
- Neuroblastoma
- Hu3F8 With GM-CSF
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 2, 2022
Neuroblastoma Trial in Houston (Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN
Active, not recruiting
- Neuroblastoma
- Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells
- Cytoxan
-
Houston, TexasTexas Children's Hospital
Mar 25, 2022
Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)
Active, not recruiting
- Neuroblastoma
- High-Risk
- cyclophosphamide
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 14, 2022
Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)
Recruiting
- Neuroblastoma
- Naxitamab monotherapy
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 31, 2023
Recurrent Neuroblastoma Trial in Germany (metronomic therapy)
Recruiting
- Recurrent Neuroblastoma
- metronomic therapy
-
Bonn, Germany
- +7 more
Nov 3, 2022
Neuroblastoma Trial in New York (External beam radiotherapy, proton beam RT)
Recruiting
- Neuroblastoma
- External beam radiotherapy
- proton beam RT
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 29, 2021
Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)
Active, not recruiting
- Neuroblastoma (NB)
- Irinotecan
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 19, 2021
Neuroblastoma Trial in Pilar, Buenos Aires (Racotumomab)
Active, not recruiting
- Neuroblastoma
-
Pilar, Buenos Aires, Argentina
- +1 more
Sep 30, 2021
Neuroblastoma Trial in Houston (SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2
Active, not recruiting
- Neuroblastoma
- SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
- SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
-
Houston, TexasTexas Children's Hospital
Mar 3, 2022
Neuroblastoma Trial in New York (adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH,
Active, not recruiting
- Neuroblastoma
- adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
- oral β-glucan
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 11, 2021
Neuroblastoma, CNS Tumor, Sarcoma Trial in Columbus (Cabozantinib)
Recruiting
- Neuroblastoma
- +2 more
-
Columbus, OhioNationwide Children's Hospital
Dec 20, 2022